191 related articles for article (PubMed ID: 18319058)
1. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.
Li Y; Zhang W; Guo D; Zhou G; Zhou H; Xiao Z
Clin Chim Acta; 2008 May; 391(1-2):60-7. PubMed ID: 18319058
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
3. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial.
Wang L; Zhou L; Hu H; Lin S; Xia J
Curr Med Res Opin; 2012 Jan; 28(1):101-9. PubMed ID: 22070512
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
Yoo HD; Cho HY; Lee YB
Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
[TBL] [Abstract][Full Text] [Related]
5. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study.
DU YQ; Guo WY; Zou DW; Zhan XB; Li Z; Hu JH; Gong YF; He J; Lu JP; Li ZS
J Dig Dis; 2012 Feb; 13(2):113-9. PubMed ID: 22257480
[TBL] [Abstract][Full Text] [Related]
6. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects.
Kim KA; Song WK; Park JY
Clin Pharmacol Ther; 2009 Nov; 86(5):511-8. PubMed ID: 19693007
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
de Bortoli N; Martinucci I; Giacchino M; Blandizzi C; Marchi S; Savarino V; Savarino E
Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1361-9. PubMed ID: 23802731
[TBL] [Abstract][Full Text] [Related]
9. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5.
Seo KA; Lee SJ; Kim KB; Bae SK; Liu KH; Kim DH; Shin JG
Xenobiotica; 2012 Mar; 42(3):278-84. PubMed ID: 22022918
[TBL] [Abstract][Full Text] [Related]
10. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
GawroĊska-Szklarz B; Adamiak-Giera U; Wyska E; Kurzawski M; Gornik W; Kaldonska M; Drozdzik M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1267-74. PubMed ID: 22418828
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
Yoo HD; Park SA; Cho HY; Lee YB
Clin Pharmacol Ther; 2009 Sep; 86(3):281-4. PubMed ID: 19516253
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
[TBL] [Abstract][Full Text] [Related]
15. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
Sugimoto K; Uno T; Tateishi T
Eur J Clin Pharmacol; 2008 Jun; 64(6):583-7. PubMed ID: 18214455
[TBL] [Abstract][Full Text] [Related]
16. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.
Xu HR; Chen WL; Li XN; Chu NN
Pharm Biol; 2010 Aug; 48(8):947-52. PubMed ID: 20673183
[TBL] [Abstract][Full Text] [Related]
17. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
19. Impact of the CYP2C19*17 polymorphism on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.
Mazer-Amirshahi M; van den Anker J
J Clin Pharmacol; 2013 Mar; 53(3):359. PubMed ID: 23381740
[No Abstract] [Full Text] [Related]
20. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]